FilingsTodayHome › US companies › Summit Therapeutics
Summit Therapeutics
SMMT · Nasdaq · Pharmaceutical Preparations
Insider buys (12 months)
$52.2M
Insider sales (12 months)
0
8-K reports (12 months)
18
Tracked investors holding
0
At a glance
Summit Therapeutics reported 2024 revenue of $0. Revenue peaked in 2021 at $1.8M. The company posted a loss in 2021, 2022, 2023, 2024 and 2025.
In the last 12 months 2 insiders reported 3 open-market purchases ($52.2M) and 0 sales. The largest was a purchase of $50M by Co-Chief Executive Officer Robert W Duggan on Jun 12, 2026.
Summit Therapeutics filed 18 current reports (Form 8-K) in the last 12 months, most often for other events (10), results of operations (4), material agreement (2) and unregistered equity sale (1). It reported a material agreement or a completed acquisition or disposal 2 times.
Annual results
2021
Revenue $1.8M
Op. -$86.2M
2022
Revenue $705K
Op. -$72.1M
2023
Revenue $0
Op. -$609.6M
2024
Revenue $0
Op. -$226M
2025
Revenue -
Net -$1.08B
RevenueOperating income (or net income)SEC XBRL annual filings, fiscal years mapped to calendar years
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$88.6M | -$78.8M | -$614.9M | -$221.3M | -$1.08B |
| Diluted EPS | $-0.67 | $-0.41 | $-0.99 | $-0.31 | $-1.44 |
Fiscal year ends Dec 31
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined